Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.

about

Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.

P2860

Q37709464-34B75DA5-9513-48F9-8B69-B38EB4B38E44

P2860

Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.

Item

http://www.wikidata.org/entity/Q41304112

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Metabolic behavior prediction ...... CYP) 3A4 by molecular docking.

@en

type

Item

label

Metabolic behavior prediction ...... CYP) 3A4 by molecular docking.

@en

prefLabel

Metabolic behavior prediction ...... CYP) 3A4 by molecular docking.

@en

P1476

Metabolic behavior prediction ...... CYP) 3A4 by molecular docking.

@en

P2093

Ben-Kang Shi

http://www.w3.org/2001/XMLSchema#string

Hua Lu

http://www.w3.org/2001/XMLSchema#string

Ju-Xiang Sun

http://www.w3.org/2001/XMLSchema#string

Su-Rong Wang

http://www.w3.org/2001/XMLSchema#string

Xing-Jie Liu

http://www.w3.org/2001/XMLSchema#string

Xing-Sheng Yang

http://www.w3.org/2001/XMLSchema#string

Yan-Shuai Mo

http://www.w3.org/2001/XMLSchema#string

P2860

Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4

A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer

Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile

The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer

Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?

Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer.

Bioactivation of herbal constituents: simple alerts in the complex system.

MicroRNAs as prognostic markers in ovarian cancer.

P2888

s13318-015-0252-y

P304

465-468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13318-015-0252-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1020408020

http://www.w3.org/2001/XMLSchema#string

P698

25737032

http://www.w3.org/2001/XMLSchema#string

Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.

about

P2860

P2860

Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698